SOURCE: Oracle Corporation

Oracle Corporation

September 30, 2015 08:00 ET

Large South Korean Contract Research Organization Selects Oracle Health Sciences InForm to Speed Clinical Trials

LSK Global PS Optimizes Clinical Development Processes With Oracle Health Sciences Cloud Solution

REDWOOD SHORES, CA--(Marketwired - Sep 30, 2015) - Oracle (NYSE: ORCL)

Oracle Health Sciences (NYSE: ORCL) today announced that LSK Global Pharma Services (LSK Global PS), the leading full-service contract research organization (CRO) in South Korea, has adopted cloud-based Oracle Health Sciences InForm to improve its clinical development processes, streamline data capture, and speed up trial timelines.

LSK Global PS offers task flow, product development, regulatory consulting, project development, clinical research, data management, and other CRO services. The company also conducts clinical trials for many local pharmaceutical firms. LSK Global PS looked to Oracle for a solution that would enable its R&D team to access real-time clinical trial data, reduce invalid data entries, and expedite the availability of drug trial information.

LSK Global PS plans to utilize Oracle's best-in-class technology to gain deeper and faster insight into its clinical data, which will help the company save time and effort. In turn, the CRO will be able to help sponsors improve the speed, quality, and efficiency of their clinical studies.

Oracle Health Sciences InForm offers comprehensive support for industry standards, such as CDISC, to increase efficiency and time for trial design and setup and enhance data collection and reporting quality.

"LSK Global PS is the first CRO in South Korea to conduct a successful global new-drug development clinical study. It is our goal to advance Korean domestic clinical trial quality standards to those at the global level," said Dr.Young Jack Lee, chairman and chief executive officer, LSK Global PS. "To support our growing global business needs, the Oracle Health Sciences InForm electronic data capture system provides us with the confidence to meet our expanding global customer demands and helps ensure that we have access to accurate data at all times."

In addition, with Oracle Health Sciences InForm's intuitive dynamic data entry displays, LSK Global PS will be able to accelerate data collection and improve the end user experience at clinical investigator sites.

"Today, CROs are challenged by increasingly complex global clinical trials, shrinking R&D resources, and smaller budgets -- all in a more competitive environment," said Steve Rosenberg, senior vice president and general manager, Oracle Health Sciences. "With more than 15 years of electronic data capture experience in the clinical industry, Oracle Health Sciences helps leading CROs -- such as LSK Global PS -- to not only optimize their study start-up processes, but to also be prepared with value-based clinical innovation solutions that enable a strategic advantage for their sponsor customers."

Oracle and the Galien Foundation
Through its solutions, Oracle Health Sciences helps global CROs such as LSK Global PS push clinical trial boundaries and create an environment for innovation and discovery.

Extending its commitment to health science innovation, Oracle Health Sciences will be participating in the sixth annual Galien Forum and Prix Galien USA awards ceremony. The Galien Foundation is internationally renowned for recognizing the development of innovative medicines and medical technologies that advance pharmaceutical research and improve the state of human health.

Additional Information
To learn more about Oracle Health Sciences, please connect on Twitter @OracleHealthSci and at facebook.com/oraclehealthsciences, or visit oracle.com/health-sciences.

About Oracle
Oracle offers a comprehensive and fully integrated stack of cloud applications and platform services. For more information about Oracle (NYSE: ORCL), visit oracle.com.

Trademarks
Oracle and Java are registered trademarks of Oracle and/or its affiliates. Other names may be trademarks of their respective owners.

Contact Information